This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
附属机构
This person is not affiliated with any business or Blue Board record at ProZ.com.
原文文本 - English英语 Background:
Schizophrenia is a chronic debilitating illness with a prevalence of approximately 1% in the
general population worldwide, affecting over 3 million individuals in the US. Of this total,
almost 2.9 million individuals are diagnosed and 92% receive drug therapy. The World
Health Organization’s Global Burden of Disease 2000 ranked schizophrenia as the fifth
leading cause of years lived with a disability. At the forefront of current treatment options
are atypical antipsychotic drugs (APDs). Compared with first generation agents such as
haloperidol, atypical APDs have comparable efficacy in treating positive symptoms of
schizophrenia (eg, delusions and hallucination), but lower risk for extrapyramidal motor
adverse events. However, even with the improvements in toleration and efficacy, the unmet
medical need in schizophrenia is still high. Schizophrenia patients stabilized on APDs have
been documented to exhibit ongoing cognitive impairment1 that is associated with continuing
functional impairment.
Study Rationale:
This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to
evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of
XXX oral CR formulation in Japanese male subjects over the dose range of 20 to
60 mg single doses and at 40 mg twice daily (BID) for 7 days (40 mg single dose on the last
day). Based on in vitro metabolism data, PF-03463275 is mainly metabolized by CYP2D6.
Since 20-35% of the Asian population including Japanese are known to be intermediate
metabolizers (IMs),3 genotyping of CYP2D6 will be conducted for enrollment in this study to
investigate the potential relationship between the exposure of PF-03463275 and CYP2D6
genotype. Subject selection will only include Japanese and Western (defined as non-Asian)
patients subjects with an EM (extensive metabolizer) or IM (intermediate metabolizer)
CYP2D6 genotype. Additionally, this study will compare the pharmacokinetics, safety and
tolerability of XXX between Japanese and Western male subjects.
原文文本 - English英语 No serious adverse events (SAE) and no death were reported in the present study.
A total of 13 adverse events (AE) were reported in 10 included participants, all were emergent adverse events (EAEs). None of the EAEs was considered as related to the study treatments according to the investigator’s opinion. All EAEs were of mild intensity and all were recovered at the end of the study.
The most frequently reported emergent adverse events were:
- Headache: 3 EAEs in 3 participants (2 following S 06611 1.2 g administration and 1 following S 12911 2 g administration),
- Oropharyngeal pain: 3 EAEs in 3 participants (2 following S 06611 1.2 g administration and 1 following S 12911 2 g administration),
- Nasopharyngitis: 3 EAEs in 3 participants (1 following S 06611 1.2 g administration and 2 following S 12911 2 g administration).
No participant withdrew due to adverse event.
翻译文本 - Chinese汉语 当前研究未报告严重不良事件 (SAE)和死亡。.
入选的10名受试者共报告13起不良事件(AE)，所有均为引发不良事件(EAE)。根据研究者意见，无 EAEs被认为同研究治疗相关。所有EAE均为轻度，在研究结束时恢复。.
最常报告的引发不良事件包括：
- 头痛：3名受试者报告3起EAE(2名在接受1.2g S 06611治疗后，1名在接受2g S 12911治疗后)。
- 口咽疼痛：3名参与者报告3起EAE（2名在接受1.2g S 06611 治疗后，1名在接受2g S 12911治疗后)，
- 鼻咽炎：3名参与者报告3起EAE (1名在接受1.2g S 06611 治疗后，2名在接受2g S 12911治疗后).
无参与者因不良事件退出。
A freelancer with rich experience in translation of life science documents (En-CHS)
Summary of Qualifications
More than 30 million words (over 10 years) of experience in translating
English/ Simplified Chinese medical documents including clinical trial
documents.
Master of Medicine degree
Native fluency in Simplified Chinese – spoken and written
Fluency in English – spoken and written
5-year experience as a clinical doctor
A CAT user
Excellent interpersonal skills, and ability to work in a team
environment.
Education and Professional Training
Changzheng Hospital,
the 2nd Military Medical University, Shanghai 2005
-2008
Master of Medicine
Fields: systemic fungal infection and dermatology
· National Center of
Nanotechnology and Science, CAS, Beijing 2007
Visiting Scholar
The 2nd Military
Medical University, Shanghai 1996-2001
翻译样本 